Setting Up a Haplobank: Issues and Solutions

被引：29

作者：

Barry J. ^{[1
]}

Hyllner J. ^{[1
,2
]}

Stacey G. ^{[3
]}

Taylor C.J. ^{[4
]}

Turner M. ^{[5
,6
]}

机构：

[1] Cell Therapy Catapult, 12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London

[2] Division of Biotechnology/IFM, Linköping University, Linköping

[3] National Institute of Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, Hertfordshire

[4] Histocompatibility and Immunogenetics (Tissue Typing) Laboratory (Box 209), Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Hills Road, Cambridge

[5] Scottish National Blood Transfusion Service, 21 Ellen’s Glen Road, Edinburgh, EH17 7QT, Scotland

[6] Scottish Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, Scotland

来源：

Current Stem Cell Reports | 2015年 / 1卷 / 2期

基金：

英国医学研究理事会;

关键词：

Good manufacturing practice; HLA matching; Induced pluripotent stem cells;

D O I：

10.1007/s40778-015-0011-7

中图分类号：

学科分类号：

摘要：

The development of induced pluripotent stem cells offers the possibility of the scalable manufacture of cellular therapies for regenerative medicine. Moreover, donors can be selected on the basis of major transplant antigen systems to match the widest possible number of recipients worldwide, reducing the likely risk of immunological rejection and the degree of immune suppression or tolerance required. If such cell lines are to be broadly available, there will need to be mutual recognition of common standards across different jurisdictions. Extensive international collaboration will be required around issues such as determination of the optimal homozygous human leukocyte antigens (HLA) panel, donor selection, screening and consent, good manufacturing practice (GMP), standards and quality control and regulatory legislation. The challenges in establishing a global GMP induced pluripotent stem cell (iPSC) haplobank are formidable. We argue that now is the time to attempt to reach international agreement around common standards for GMP iPSC manufacture before the field develops in a fragmented manner. © 2015, The Author(s).

引用

页码：110 / 117

页数：7

共 26 条

[1]

Taylor C.J., Bolton E.M., Pocock S., Sharples L.D., Pedersen R.A., Bradley J.A., Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching, Lancet, 366, 9502, pp. 2019-2025, (2005)

[2]

Taylor C.J., Bolton E.M., Bradley J.A., Immunological considerations for embryonic and induced pluripotent stem cell banking, Philos Trans R Soc Lond B Biol Sci, 366, 1575, pp. 2312-2322, (2011)

[3]

Gourraud P.A., Gilson L., Girard M., Peschanski M., The role of human leukocyte antigen matching in the development of multiethnic “haplobank” of induced pluripotent stem cell lines, Stem Cells, 30, 2, pp. 180-186, (2012)

[4]

Taylor C.J., Peacock S., Chaudhry A.N., Bradley J.A., Bolton E.M., Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types, Cell Stem Cell, 11, 2, pp. 147-152, (2012)

[5]

Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Et al., A more efficient method to generate integration-free human iPS cells, Nat Methods, 8, 5, pp. 409-412, (2011)

[6]

Turner M., Leslie S., Martin N.G., Peschanski M., Rao M., Taylor C.J., Et al., Toward the development of a global induced pluripotent stem cell library, Cell Stem Cell, 13, 4, pp. 382-384, (2013)

[7]

Nakatsuji N., Nakajima F., Tokunaga K., HLA-haplotype banking and iPS cells, Nat Biotechnol, 26, 7, pp. 739-740, (2008)

[8]

Nakajima F., Tokunaga K., Nakatsuji N., Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy, Stem Cells, 25, 4, pp. 983-985, (2007)

[9]

Lin G., Xie Y., Ouyang Q., Qian X., Xie P., Zhou X., Et al., HLA-matching potential of an established human embryonic stem cell bank in China, Cell Stem Cell, 5, 5, pp. 461-465, (2009)

[10]

Tissues and Organs, Donation of starting material for cell-based advanced therapies, (2014)

← 1 2 3 →